Press Room

XXVII National Congress of the Portuguese Chemistry Society

Start
Wednesday, July 14, 2021 - 09:00
End
Friday, July 16, 2021 - 18:00
XXVII National Congress of the Portuguese Chemistry Society | Hovione

Hovione sponsors and participates at the XXVII National Congress of the Portuguese Chemistry Society with two scientific presentations:

 

Presentation 1

14 July, 16h10
Calorimetry of NBS in DMF: unstable or understudied?

Speaker: Elsa Gonçalves – Process Safety Scientist, Process Chemistry Development

Abstract: The presentation portrays the contribution of the Process Safety team to ensure the safety and improvement of the chemical processes being conducted at the Hovione plant. Elsa will present a recent case study in which the Process safety input was crucial for the optimization of the process, reducing its hazardous and increasing its efficiency.

 

Presentation 2

15 July, 16h30
Low-field Benchtop NMR for solvent swap analysis

 

Speaker: Marta Andrade – Scientist, Process Chemistry Development

Abstract: The presentation will show the results of an extensive study using a benchtop low-field NMR spectrometer (1H-NMR, 43 MHz) to quantify solvents in 20 binary systems that are commonly used for swap process under API manufacture processes. The exciting results open the way to use benchtop low-field NMR as PAT tool for real time solvent swap in-process control, saving time and resources.

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026